)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Filana Therapeutics
Filana Therapeutics (FLNA) investor relations material
Filana Therapeutics Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary5 Nov, 2026
Executive summary
Q3 net loss was $10.7M, versus $10.8M a year earlier; 9M net loss narrowed to $29.7M from $78.4M, primarily reflecting lower operating expenses after the Alzheimer’s program wind-down and lower prior-year legal charges.
FDA lifted the clinical hold on simufilam for TSC-related epilepsy in September 2026; Phase 2a patient screening is targeted by Q1 2027.
Financial highlights
Q3 operating expenses and operating loss were $11.3M, down from $11.9M; R&D was $3.9M versus $4.0M and G&A was $7.4M versus $7.9M.
9M operating expenses were $31.8M versus $81.8M; R&D was $11.7M versus $22.7M and G&A was $20.1M versus $59.1M.
9M net loss was $29.7M versus $78.4M, or $0.61 versus $1.62 per share; Q3 loss per share was $0.22 in both years.
No product revenue; 9M operating cash use was $18.8M versus $22.5M, and cash and cash equivalents were $47.0M at September 30, 2026, with no debt.
Outlook and guidance
Planned 16-week Phase 2a study in refractory TSC-related seizures targets ~40 patients ages 12–55 at ~13 U.S. sites; screening is expected by Q1 2027.
H2 2026 operating cash use was forecast at $11M–$15M, with year-end cash and cash equivalents estimated at $38M–$42M.
Near-term R&D spending for TSC-related epilepsy is expected to be significantly lower than for the former Alzheimer’s program; G&A is also expected to decrease.
Cash and cash equivalents are expected to fund operations for at least 12 months; future financing may be sought, with availability and terms uncertain.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Filana Therapeutics
- Simufilam advances as a first-in-class TSC epilepsy therapy, supported by strong data and financial stability.FLNA
Corporate presentation - Net loss narrowed as costs fell; simufilam’s TSC trial remains on FDA hold amid litigation settlement.FLNAQ2 2026
- All proposals passed as the company focuses on resolving the FDA clinical hold for its TSC program.FLNAAGM 2026
- Simufilam shows promise as a first-in-class TSC epilepsy therapy, with strong preclinical data and robust safety.FLNACorporate presentation
- Net loss narrowed and expenses fell as focus shifted to TSC epilepsy, pending FDA review.FLNAQ1 2026
- Key votes include director elections, equity plan expansion, and auditor ratification.FLNAProxy filing
- 2025 loss widened on one-time items; focus shifts to TSC epilepsy with strong cash reserves.FLNAQ4 2025
- Advancing simufilam for TSC-related epilepsy, targeting a large unmet need with strong preclinical data.FLNAInvestor presentation
- Strategic shift to TSC epilepsy, phase II-A trial in 2026, strong safety and financials.FLNAH.C. Wainwright 27th Annual Global Investment Conference
Next Filana Therapeutics earnings date
Q4 202612 Mar, 2027
Filana Therapeutics
Next Filana Therapeutics earnings date
Q4 202612 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Cassava Sciences, Inc. is a clinical-stage biotechnology company focused on developing novel treatments for neurodegenerative diseases, with a primary focus on Alzheimer’s disease. The company’s leading drug candidate, simufilam, is an oral small molecule in 3 clinical trials aimed at treating Alzheimer’s by targeting an altered form of a brain protein known as filamin A. Cassava Sciences is also developing SavaDx, an investigational diagnostic tool designed to detect Alzheimer's disease through a blood test. The company is headquartered in Austin, Texas, and its shares are listed on the NASDAQ.